Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
COVID‐19
Heart failure
Hypertrophic cardiomyopathy
Prognosis
Registry
SARS‐CoV‐2 infection
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
22
04
2022
received:
19
01
2022
accepted:
27
04
2022
entrez:
18
10
2022
pubmed:
19
10
2022
medline:
21
10
2022
Statut:
ppublish
Résumé
To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
Identifiants
pubmed: 36255281
doi: 10.1002/ehf2.13964
pmc: PMC9288745
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2189-2198Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001879
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Investigateurs
Carmen Muñoz-Esparza
(C)
José Manuel García-Pinilla
(JM)
Ainhoa Robles-Mezcua
(A)
María Victoria Moreno-Flores
(MV)
María Luisa Peña
(ML)
Marco Merlo
(M)
David Vaqueriza Cubillo
(DV)
Vicente Climent-Payá
(V)
Elena Dankovtseva
(E)
Alejandro Rodríguez Vilela
(AR)
Pablo García-Pavía
(P)
Guillem Casas
(G)
Informations de copyright
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Circ Res. 2021 Apr 16;128(8):1214-1236
pubmed: 33856918
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur Heart J. 2008 Jan;29(2):270-6
pubmed: 17916581
Sci Rep. 2021 Apr 19;11(1):8449
pubmed: 33875742
Eur Heart J. 2018 May 21;39(20):1784-1793
pubmed: 29378019
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Am Coll Cardiol. 2020 Nov 3;76(18):2043-2055
pubmed: 33121710
Heart. 2005 Jul;91(7):920-5
pubmed: 15958362
Circulation. 2006 Apr 11;113(14):1807-16
pubmed: 16567565
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Circulation. 2018 Oct 2;138(14):1387-1398
pubmed: 30297972